Skip to main content
. 2018 Nov 24;63(3):563–572. doi: 10.1007/s12020-018-1792-0

Fig. 1.

Fig. 1

Cross-sectional analyses in patients with acromegaly treated with pegvisomant: Blood Glucose levels a and HbA1c b over time (yearly evaluations)